## Aleksandar Dagovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4445390/publications.pdf Version: 2024-02-01

		394421	454955
33	1,561	19	30
papers	citations	h-index	g-index
33	33	33	1388
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Primary Small Cell Carcinoma Of Lung With Metachronous Breast Metastasis. Serbian Journal of Experimental and Clinical Research, 2017, 18, 263-267.	0.1	0
2	Trends and Patterns of Disparities in Oral Cavity and Pharyngeal Cancer in Serbia: Prevalence and Economic Consequences in a Transitional Country. Frontiers in Pharmacology, 2017, 8, 385.	3.5	2
3	Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery. Serbian Journal of Experimental and Clinical Research, 2015, 16, 43-50.	0.1	9
4	Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols. Expert Review of Anticancer Therapy, 2015, 15, 963-970.	2.4	12
5	Radiation therapy remains the key cost driver of oncology inpatient treatment. Journal of Medical Economics, 2015, 18, 29-36.	2.1	28
6	Economics of cancer related medical care: Worldwide estimates and available domestic evidence. Archive of Oncology, 2011, 19, 59-63.	0.2	11
7	Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer. Archive of Oncology, 2007, 15, 10-14.	0.2	2
8	Pretreatment prognostic factors in patients with early-stage (I/II) non–small-cell lung cancer treated with hyperfractionated radiation therapy alone. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1112-1119.	0.8	16
9	Radiochemotherapy in Locally Advanced Non-Small Cell Lung Cancer. , 2005, , 207-222.		0
10	Radiation Therapy With or Without Concurrent Low-Dose Daily Chemotherapy in Locally Advanced, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2004, 22, 3540-3548.	1.6	72
11	Combined treatment modality for anaplastic oligodendroglioma and oligoastrocytoma: a 10-year update of a Phase II study. International Journal of Radiation Oncology Biology Physics, 2004, 59, 509-514.	0.8	13
12	Stage III Non–Small-Cell Lung Cancer Treated With High-Dose Hyperfractionated Radiation Therapy and Concurrent Low-Dose Daily Chemotherapy With or Without Weekend Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 350-360.	1.3	6
13	Clinical Prognostic Factors in Patients With Malignant Glioma Treated With Combined Modality Approach. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 195-204.	1.3	38
14	Interfraction Interval in Patients With Stage III Non-Small-Cell Lung Cancer Treated With Hyperfractionated Radiation Therapy With or Without Concurrent Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 616-625.	1.3	9
15	Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. Journal of Cancer Research and Clinical Oncology, 2003, 129, 114-122.	2.5	35
16	Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. Journal of Cancer Research and Clinical Oncology, 2003, 129, 477-484.	2.5	62
17	Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: A 10-year update of a Phase II study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 465-471.	0.8	21
18	Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer, 2003, 40, 317-323.	2.0	29

#	Article	IF	CITATIONS
19	No thoracic radiation myelitis after spinal cord dose ≥50.4 Gy using 1.2. Gy b.i.d. fractionation in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy. Lung Cancer, 2002, 35, 287-292.	2.0	6
20	Second Cancers Occurring in Patients With Early Stage Non–Small-Cell Lung Cancer Treated With Chest Radiation Therapy Alone. Journal of Clinical Oncology, 2001, 19, 1056-1063.	1.6	41
21	Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non–small-cell lung cancer: A randomized trial. International Journal of Radiation Oncology Biology Physics, 2001, 50, 19-25.	0.8	50
22	Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. Journal of Neuro-Oncology, 2001, 51, 133-141.	2.9	26
23	Elective ipsilateral neck irradiation of patients with locally advanced maxillary sinus carcinoma. , 2000, 88, 2246-2251.		29
24	Hyperfractionated Radiation Therapy With or Without Concurrent Low-Dose Daily Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial. Journal of Clinical Oncology, 2000, 18, 1458-1464.	1.6	442
25	A phase ii study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage iii non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 1999, 44, 343-348.	0.8	47
26	Combined treatment modality for anaplastic oligodendroglioma: a phase II study. Journal of Neuro-Oncology, 1999, 43, 179-185.	2.9	27
27	Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. Journal of Neuro-Oncology, 1999, 44, 85-90.	2.9	27
28	External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection. Lung Cancer, 1999, 23, 135-142.	2.0	55
29	Prolonged oral versus high-dose intravenous etoposide in combination with carboplatin for stage IV non-small-cell lung cancer (NSCLC): a randomized trial. Lung Cancer, 1999, 25, 207-214.	2.0	9
30	Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study. Radiotherapy and Oncology, 1999, 51, 27-33.	0.6	27
31	Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer: A Randomized Study. Journal of Clinical Oncology, 1999, 17, 2092-2092.	1.6	328
32	Concurrent radiochemotherapy for patients with stage III non-small–cell lung cancer (NSCLC): long-term results of a phase II study. International Journal of Radiation Oncology Biology Physics, 1998, 42, 1091-1096.	0.8	54
33	Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma. A phase II study. Radiotherapy and Oncology, 1998, 49, 49-54.	0.6	28